Limelight Bio

About:

Limelight is building an industry-leading platform to develop technologies, advanced targets, and leading drug candidates.

Website: https://www.limelightbio.com/

Top Investors: Apple Tree Partners

Description:

Limelight Bio is a multi-platform, multi-disease focused biopharmaceutical company expanding the limits of gene therapy. The company is developing novel gene therapies that greatly expand the utility of clinically-validated AAV vectors to enable the treatment of debilitating inherited diseases that cannot be addressed by current technologies; such as those caused by mutations in large genes and autosomal dominant inheritance patterns. Limelight Bio's proprietary technologies are designed to overcome limitations of currently available viral-based treatments to address a wider range of diseases. It was founded in 2016 and is headquartered in Philadelphia, Pennsylvania, United States.

Total Funding Amount:

$89M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Philadelphia, Pennsylvania, United States

Founded Date:

2016-01-01

Founders:

Jean Bennett

Number of Employees:

1-10

Last Funding Date:

2019-12-05

IPO Status:

Private

Industries:

© 2025 bioDAO.ai